Jazz Pharmaceuticals Director Ted W. Love Files Form 144 to Sell $373K in Stock
Jazz Pharmaceuticals plc
Subscribe to track JAZZ
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Form 144 Filing Alert: Jazz Pharmaceuticals plc • Insider: Ted W. Love (Director) • Proposed Sale: 1,527 Common shares • Estimated Market Value: $373,413.00 (~$244.54/share) • Broker: E*TRADE Financial Corporation • Acquisition Source: Restricted Stock Vesting (Acquired 08/28/2026) • Approx. Sale Date: 08/31/2026
Comprehensive Analysis
Insider Filing Analysis: Form 144 Notice of Proposed Sale
Issuer: Jazz Pharmaceuticals plc (CIK: 0001232524)
Insider: Ted W. Love, Director (CIK: 0001188919)
Filing Date: August 31, 2026
Filing Accession: 0001188919-26-000013
Transaction Summary
- Securities Proposed for Sale: 1,527 Common Shares
- Aggregate Market Value: $373,413.00
- Implied Price per Share: ~$244.54
- Approximate Sale Date: August 31, 2026
- Broker: E*TRADE Financial Corporation
- Shares Outstanding: 64,914,577
Origin of Shares
- Date Acquired: August 28, 2026
- Nature of Acquisition: Restricted Stock Vesting (Equity Compensation)
- Securities Acquired: 1,527 shares
Significance & Market Impact
- Significance Rating: Low
- Context: The proposed sale represents a small transaction size ($373.4K) and corresponds directly to shares acquired via a recent restricted stock vesting on August 28, 2026. This type of transaction is common for board members liquidating equity compensation upon vesting.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.